Adalimumab is a medicine on which hospitals spend more than £400 million a year. The patent has now expired, allowing patients to be treated with a cheaper biosimilar, saving around £150 million per year (which can be re-directed to better purpose). Another one-off step in the right direction:
NHS set to save £150 million by switching to new versions of most costly drug. [Online]: NHS England, October 16th 2018.
A wider, bigger-picture and more ambitious vision of the underlying principles which could have greater influence in national pricing and purchasing policy:
Mazzucato, M. Chow, H. [and] Fitzpatrick, S. [et al] (2018). The people’s prescription: re-imagining health innovation to deliver public value. London: UCL Institute for Innovation and Public Purpose, October 2018.
Voluntary Scheme for Branded Medicines Pricing and Access
The Pharmaceutical Pricing Regulation Scheme (PPRS) will become the Voluntary Scheme for Branded Medicines Pricing and Access.
Pym, H. (2018). Deal gives patients faster drug access. London: BBC Health News, November 23rd 2018.